Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study

U Baber, G Dangas, DJ Cohen, CM Gibson… - American heart …, 2016 - Elsevier
Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …
被引用次数：121 相关文章

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study

U Baber, G Dangas, DJ Cohen, CM Gibson… - American Heart …, 2016 - infona.pl
Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet increases bleeding
after percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Antiplatelet …

[引用][C] Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study

U Baber, G Dangas, DJ Cohen, CM Gibson… - American Heart …, 2016 - cir.nii.ac.jp
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and
design of the TWILIGHT study | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.

U Baber, G Dangas, DJ Cohen, CM Gibson, SR Mehta… - 2016 - mediatum.ub.tum.de
Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet increases bleeding
after percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Antiplatelet …

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.

U Baber, G Dangas, DJ Cohen… - American heart …, 2016 - researchonline.lshtm.ac.uk
BACKGROUND: Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study

U Baber, G Dangas, DJ Cohen, CM Gibson, SR Mehta… - 2016 - pubmed.ncbi.nlm.nih.gov
Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.

U Baber, G Dangas, DJ Cohen, CM Gibson… - American Heart …, 2016 - europepmc.org
Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …

[引用][C] Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study

U Baber, G Dangas, DJ Cohen, CM Gibson… - The American Heart …, 2016 - Elsevier Limited